Vericel (VCEL) Other Non-Current Assets (2019 - 2026)
Vericel (VCEL) posted Other Non-Current Assets of $233000.0 for Q2 2026, down 19.1% sequentially from $288000.0 in Q1 2026, and down 47.87% YoY from $447000.0 in Q2 2025.
Vericel (VCEL) Other Non-Current Assets (2019 - 2026) Analysis & Trends
Vericel has reported Other Non-Current Assets for 8 years, with the latest figure at $233000.0 in Q2 2026.
- Quarterly Other Non-Current Assets fell 47.87% year-over-year to $233000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $233000.0 (down 47.87% YoY) and the FY2025 annual result came in at $341000.0, down 38.67% from the prior year.
- Other Non-Current Assets fell to $233000.0 in Q2 2026 per VCEL's latest filing, from $288000.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $43.0 million in Q2 2023 and troughed at $233000.0 in Q2 2026.
- A 5-year average of $3.7 million and a median of $690500.0 in 2024 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2022 and 2024: Other Non-Current Assets soared 2830.81% in 2022, then tumbled 98.46% in 2024.
- Over 5 years, Other Non-Current Assets stood at $1.3 million in 2022, then plunged by 40.83% to $771000.0 in 2023, then dropped by 27.89% to $556000.0 in 2024, then slumped by 38.67% to $341000.0 in 2025, then sank by 31.67% to $233000.0 in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $233000.0, $288000.0, and $341000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Vericel | 2.26 Bn | 2.10 Bn | 56.40 Mn | 233,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 233,000.00 |
| Mar 31, 2026 | 288,000.00 |
| Dec 31, 2025 | 341,000.00 |
| Sep 30, 2025 | 395,000.00 |
| Jun 30, 2025 | 447,000.00 |
| Mar 31, 2025 | 501,000.00 |
| Dec 31, 2024 | 556,000.00 |
| Sep 30, 2024 | 610,000.00 |
| Jun 30, 2024 | 664,000.00 |
| Mar 31, 2024 | 717,000.00 |
| Dec 31, 2023 | 771,000.00 |
| Sep 30, 2023 | 1.14 Mn |
| Jun 30, 2023 | 1.20 Mn |
| Mar 31, 2023 | 1.25 Mn |
| Dec 31, 2022 | 1.30 Mn |
| Sep 30, 2022 | 1.36 Mn |
| Jun 30, 2022 | 317,000.00 |
| Mar 31, 2022 | 317,000.00 |
| Dec 31, 2021 | 211,000.00 |
| Sep 30, 2021 | 211,000.00 |